The Manufacturers Life Insurance Company Purchases 8,557 Shares of LivaNova PLC (LIVN)
The Manufacturers Life Insurance Company boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 8.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 105,580 shares of the company’s stock after buying an additional 8,557 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in LivaNova were worth $8,438,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Cerebellum GP LLC acquired a new position in LivaNova during the 4th quarter worth about $128,000. Pillar Pacific Capital Management LLC acquired a new position in LivaNova during the 4th quarter worth about $208,000. Shelton Capital Management acquired a new position in LivaNova during the 3rd quarter worth about $209,000. Affinity Investment Advisors LLC acquired a new position in LivaNova during the 4th quarter worth about $211,000. Finally, Crossmark Global Holdings Inc. acquired a new position in LivaNova during the 3rd quarter worth about $263,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $82.15, for a total value of $82,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 3,000 shares of company stock valued at $246,270. Corporate insiders own 0.28% of the company’s stock.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.88 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.10. LivaNova had a positive return on equity of 9.37% and a negative net margin of 2.10%. The firm had revenue of $278.40 million during the quarter, compared to analyst estimates of $278.48 million. During the same period last year, the company posted $0.83 EPS. The business’s quarterly revenue was up 11.5% on a year-over-year basis. research analysts predict that LivaNova PLC will post 3.54 earnings per share for the current year.
Several brokerages have commented on LIVN. Needham & Company LLC reaffirmed a “buy” rating and set a $104.00 target price (up from $97.00) on shares of LivaNova in a report on Wednesday, February 28th. Canaccord Genuity lifted their target price on LivaNova from $76.00 to $81.00 and gave the stock a “hold” rating in a report on Tuesday, February 27th. BidaskClub raised LivaNova from a “hold” rating to a “buy” rating in a report on Wednesday, February 21st. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research downgraded LivaNova from a “hold” rating to a “strong sell” rating in a report on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $81.43.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.